{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:11:37Z","timestamp":1790403097355,"version":"4.1.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T00:00:00Z","timestamp":1529280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AG008051"],"award-info":[{"award-number":["AG008051"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS073502"],"award-info":[{"award-number":["NS073502"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["IIRG-13-283707"],"award-info":[{"award-number":["IIRG-13-283707"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13195-018-0384-9","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T20:54:00Z","timestamp":1529355240000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Immunotherapy to improve cognition and reduce pathological species in an Alzheimer\u2019s disease mouse model"],"prefix":"10.1186","volume":"10","author":[{"given":"Krystal","family":"Herline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Prelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"MacMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Go\u00f1i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-8966","authenticated-orcid":false,"given":"Thomas","family":"Wisniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,18]]},"reference":[{"key":"384_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1\u201313.","journal-title":"Alzheimers Dement"},{"key":"384_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271\u20138. discussion 278-284","journal-title":"Neurobiol Aging"},{"key":"384_CR3","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800.","journal-title":"Neurology"},{"key":"384_CR4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Van Belle G, Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurol. 1991;41:479\u201386.","journal-title":"Neurol"},{"key":"384_CR5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM. Alzheimer's disease. Lancet. 2016;388:505\u201317.","journal-title":"Lancet"},{"key":"384_CR6","first-page":"362","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns N, Davies P, Tredici KD, Duyckaerts C, Frosch MP, Hof PR, Hulette C, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee A, Montine TJ, Morris JC, Schneider JA, Sonnen JA, Thal DR, Trojanowski JQ, Troncoso JC, Wisniewski T, Woltjer RL, Beach TG. Correlation of Alzheimer's disease neuropathologic changes with cognitive status: a review of the literature. JNEN. 2012;71:362\u201381.","journal-title":"JNEN"},{"key":"384_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018;25:59\u201370.","journal-title":"Eur J Neurol"},{"issue":"6","key":"384_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608.","journal-title":"EMBO Mol Med"},{"key":"384_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jalz.2018.03.004","volume":"14","author":"N Silverberg","year":"2018","unstructured":"Silverberg N, Elliott C, Ryan L, Masliah E, Hodes R. NIA commentary on the NIA-AA Research Framework: towards a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:576\u20138.","journal-title":"Alzheimers Dement"},{"key":"384_CR10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.nbd.2009.05.024","volume":"35","author":"JL Tomic","year":"2009","unstructured":"Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis. 2009;35:352\u20138.","journal-title":"Neurobiol Dis"},{"key":"384_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860\u20136.","journal-title":"Ann Neurol"},{"key":"384_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","volume":"155","author":"LF Lue","year":"1999","unstructured":"Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol. 1999;155:853\u201362.","journal-title":"Am J Pathol"},{"key":"384_CR13","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1006\/exnr.1999.7085","volume":"158","author":"J Wang","year":"1999","unstructured":"Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol. 1999;158:328\u201337.","journal-title":"Exp Neurol"},{"key":"384_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00401-015-1386-3","volume":"129","author":"KL Viola","year":"2015","unstructured":"Viola KL, Klein WL. Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol. 2015;129:183\u2013206.","journal-title":"Acta Neuropathol"},{"key":"384_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","volume":"6","author":"U Sengupta","year":"2016","unstructured":"Sengupta U, Nilson AN, Kayed R. The role of amyloid-beta oligomers in toxicity, propagation, and immunotherapy. EBioMedicine. 2016;6:42\u20139.","journal-title":"EBioMedicine"},{"key":"384_CR16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.neuron.2014.12.064","volume":"85","author":"T Wisniewski","year":"2015","unstructured":"Wisniewski T, Goni F. Immunotherapeutic approaches for Alzheimer's disease. Neuron. 2015;85:1162\u201376.","journal-title":"Neuron"},{"key":"384_CR17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/416507a","volume":"416","author":"M Bucciantini","year":"2002","unstructured":"Bucciantini M, Giannoni E, Chiti F, Baroni F, Formiigli L, Zurdo J, Taddel N, Ramponi G, Dobson CM, Stefani M. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002;416:507\u201311.","journal-title":"Nature"},{"key":"384_CR18","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/14760584.2016.1121815","volume":"15","author":"T Wisniewski","year":"2016","unstructured":"Wisniewski T, Drummond E. Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines. 2016;15:401\u201315.","journal-title":"Expert Rev Vaccines"},{"key":"384_CR19","doi-asserted-by":"crossref","unstructured":"Drummond E, Goni F, Liu S, Prelli F, Scholtzova H, Wisniewski T. Potential novel approaches to understand the pathogenesis and treat Alzheimer's disease. J Alzheimers Dis. 2018; in press","DOI":"10.3233\/JAD-179909"},{"key":"384_CR20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.bbrc.2016.06.122","volume":"477","author":"L Breydo","year":"2016","unstructured":"Breydo L, Kurouski D, Rasool S, Milton S, Wu JW, Uversky VN, Lednev IK, Glabe CG. Structural differences between amyloid beta oligomers. Biochem Biophys Res Commun. 2016;477:700\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"384_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. Subacute meningoencephalitis in a subset of patients with AD after A beta 42 immunization. Neurology. 2003;61:46\u201354.","journal-title":"Neurology"},{"key":"384_CR22","doi-asserted-by":"publisher","first-page":"9881","DOI":"10.1038\/s41598-017-10393-z","volume":"7","author":"F Goni","year":"2017","unstructured":"Goni F, Marta-Ariza M, Peyser D, Herline K, Wisniewski T. Production of monoclonal antibodies to pathologic beta-sheet oligomeric conformers in neurodegenerative diseases. Sci Rep. 2017;7:9881.","journal-title":"Sci Rep"},{"key":"384_CR23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11481-016-9722-5","volume":"12","author":"R Penninkilampi","year":"2017","unstructured":"Penninkilampi R, Brothers HM, Eslick GD. Safety and efficacy of anti-amyloid-beta immunotherapy in Alzheimer's disease: a systematic review and meta-analysis. J NeuroImmune Pharmacol. 2017;12:194\u2013203.","journal-title":"J NeuroImmune Pharmacol"},{"key":"384_CR24","doi-asserted-by":"crossref","unstructured":"Gallardo G, Holtzman DM. Antibody therapeutics targeting Abeta and tau. Cold Spring Harb Perspect Med. 2017;7:10.","DOI":"10.1101\/cshperspect.a024331"},{"key":"384_CR25","first-page":"255","volume":"4","author":"S Budd Haeberlein","year":"2017","unstructured":"Budd Haeberlein S, O'Gorman J, Chiao P, Bussiere T, von Rosenstiel P, Tian Y, Zhu Y, von Hehn C, Gheuens S, Skordos L, Chen T, Sandrock A. Clinical development of aducanumab, an anti-abeta human monoclonal antibody being investigated for the treatment of early Alzheimer's disease. J Prev Alzheimers Dis. 2017;4:255\u201363.","journal-title":"J Prev Alzheimers Dis"},{"key":"384_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3233\/JAD-160122","volume":"52","author":"F Piazza","year":"2016","unstructured":"Piazza F, Winblad B. Amyloid-related imaging abnormalities (ARIA) in immunotherapy trials for Alzheimer's disease: need for prognostic biomarkers? J Alzheimers Dis. 2016;52:417\u201320.","journal-title":"J Alzheimers Dis"},{"key":"384_CR27","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13195-018-0337-3","volume":"10","author":"F Goni","year":"2018","unstructured":"Goni F, Marta-Ariza M, Herline K, Peyser D, Boutajangout A, Mehta P, Drummond E, Prelli F, Wisniewski T. Anti-beta-sheet conformation monoclonal antibody reduces tau and Abeta oligomer pathology in an Alzheimer's disease model. Alzheimers Res Ther. 2018;10:10.","journal-title":"Alzheimers Res Ther"},{"key":"384_CR28","first-page":"262","volume":"6","author":"NS Merle","year":"2015","unstructured":"Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I: molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.","journal-title":"Front Immunol"},{"key":"384_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2047-9158-2-21","volume":"2","author":"Y Shen","year":"2013","unstructured":"Shen Y, Yang L, Li R. What does complement do in Alzheimer's disease? Old molecules with new insights. Transl Neurodegener. 2013;2:21.","journal-title":"Transl Neurodegener"},{"key":"384_CR30","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","volume":"139","author":"B Reisberg","year":"1982","unstructured":"Reisberg B, Ferris SH, De Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139:1136\u20139.","journal-title":"Am J Psychiatry"},{"key":"384_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1\u201311.","journal-title":"Acta Neuropathol"},{"key":"384_CR32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00401-017-1691-0","volume":"133","author":"E Drummond","year":"2017","unstructured":"Drummond E, Nayak S, Faustin A, Pires G, Hickman RA, Askenazi M, Cohen M, Haldiman T, Kim C, Han X, Shao Y, Safar JG, Ueberheide B, Wisniewski T. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer's disease. Acta Neuropathol. 2017;133:933\u201354.","journal-title":"Acta Neuropathol"},{"key":"384_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3233\/JAD-2010-101341","volume":"23","author":"DL Miller","year":"2011","unstructured":"Miller DL, Potempska A, Wegiel J, Mehta PD. High-affinity rabbit monoclonal antibodies specific for amyloid peptides amyloid-beta40 and amyloid-beta42. J Alzheimers Dis. 2011;23:293\u2013305.","journal-title":"J Alzheimers Dis"},{"key":"384_CR34","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1523\/JNEUROSCI.1967-16.2016","volume":"37","author":"H Scholtzova","year":"2017","unstructured":"Scholtzova H, Do E, Dhakal S, Sun Y, Liu S, Mehta PD, Wisniewski T. Innate immunity stimulation via toll-like receptor 9 ameliorates vascular amyloid pathology in Tg-SwDI mice with associated cognitive benefits. J Neurosci. 2017;37:936\u201359.","journal-title":"J Neurosci"},{"key":"384_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1742-2094-10-150","volume":"10","author":"F Goni","year":"2013","unstructured":"Goni F, Herline K, Peyser D, Wong K, Ji Y, Sun Y, Mehta P, Wisniewski T. Immunomodulation targeting of both Abeta and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models. J Neuroinflammation. 2013;10:150.","journal-title":"J Neuroinflammation"},{"key":"384_CR36","doi-asserted-by":"publisher","first-page":"e13391","DOI":"10.1371\/journal.pone.0013391","volume":"5","author":"F Goni","year":"2010","unstructured":"Goni F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, Liang FX, Kascsak R, Kascsak R, Mehta P, Wisniewski T. Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One. 2010;5:e13391.","journal-title":"PLoS One"},{"key":"384_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409\u201321.","journal-title":"Neuron"},{"key":"384_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jalz.2011.03.004","volume":"7","author":"CR Jack Jr","year":"2011","unstructured":"Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:257\u201362.","journal-title":"Alzheimers Dement"},{"key":"384_CR39","first-page":"101","volume":"2","author":"H Scholtzova","year":"2014","unstructured":"Scholtzova H, Chianchiano P, Pan J, Sun Y, Goni F, Mehta PD, Wisniewski T. Toll-like receptor 9 stimulation for reduction of amyloid \u03b2 and tau Alzheimer's disease related pathology. Acta Neuropathol Commun. 2014;2:101.","journal-title":"Acta Neuropathol Commun"},{"key":"384_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/hipo.20059","volume":"15","author":"SE Forwood","year":"2005","unstructured":"Forwood SE, Winters BD, Bussey TJ. Hippocampal lesions that abolish spatial maze performance spare object recognition memory at delays of up to 48 hours. Hippocampus. 2005;15:347\u201355.","journal-title":"Hippocampus"},{"key":"384_CR41","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1093\/brain\/aws074","volume":"135","author":"C Romberg","year":"2012","unstructured":"Romberg C, McTighe SM, Heath CJ, Whitcomb DJ, Cho K, Bussey TJ, Saksida LM. False recognition in a mouse model of Alzheimer's disease: rescue with sensory restriction and memantine. Brain. 2012;135:2103\u201314.","journal-title":"Brain"},{"key":"384_CR42","doi-asserted-by":"publisher","first-page":"e00896","DOI":"10.1002\/brb3.896","volume":"8","author":"BA Kent","year":"2018","unstructured":"Kent BA, Heath CJ, Kim CH, Ahrens R, Fraser PE, St George-Hyslop P, Bussey TJ, Saksida LM. Longitudinal evaluation of Tau-P301L transgenic mice reveals no cognitive impairments at 17 months of age. Brain Behav. 2018;8:e00896.","journal-title":"Brain Behav"},{"key":"384_CR43","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1212\/01.WNL.0000091890.32140.8F","volume":"61","author":"R Mayeux","year":"2003","unstructured":"Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD. Plasma A\u03b240 and A\u03b242 and Alzheimer's disease. Neurol. 2003;61:1185\u201390.","journal-title":"Neurol"},{"key":"384_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2006.12.010","volume":"254","author":"PD Mehta","year":"2007","unstructured":"Mehta PD, Capone G, Jewell A, Freedland RL. Increased amyloid beta protein levels in children and adolescents with Down syndrome. J Neurol Sci. 2007;254:22\u20137.","journal-title":"J Neurol Sci"},{"key":"384_CR45","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1017\/S1041610207006394","volume":"20","author":"B Reisberg","year":"2008","unstructured":"Reisberg B, Ferris SH, Kluger A, Franssen E, Wegiel J, De Leon MJ. Mild cognitive impairment (MCI): a historical perspective. Int Psychogeriatr. 2008;20:18\u201331.","journal-title":"Int Psychogeriatr"},{"key":"384_CR46","first-page":"804","volume":"140","author":"PA Boyle","year":"2017","unstructured":"Boyle PA, Yang J, Yu L, Leurgans SE, Capuano AW, Schneider JA, Wilson RS, Bennett DA. Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline. Brain. 2017;140:804\u201312.","journal-title":"Brain"},{"key":"384_CR47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.brainres.2008.03.079","volume":"1216","author":"C Hirata-Fukae","year":"2008","unstructured":"Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, Saido TC, Klein WL, Duff KE, Aisen PS, Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008;1216:92\u2013103.","journal-title":"Brain Res"},{"key":"384_CR48","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00401-009-0556-6","volume":"118","author":"WJ Streit","year":"2009","unstructured":"Streit WJ, Braak H, Xue QS, Bechmann I. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol. 2009;118:475\u201385.","journal-title":"Acta Neuropathol"},{"key":"384_CR49","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1038\/s41598-017-08604-8","volume":"7","author":"S Liu","year":"2017","unstructured":"Liu S, Park S, Allington G, Prelli F, Sun Y, Marta-Ariza M, Scholtzova H, Biswas G, Brown B, Verghese PB, Mehta PD, Kwon YU, Wisniewski T. Targeting apolipoprotein E\/amyloid beta binding by peptoid CPO_Abeta17-21 P ameliorates Alzheimer's disease related pathology and cognitive decline. Sci Rep. 2017;7:8009.","journal-title":"Sci Rep"},{"key":"384_CR50","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0197-4580(93)90043-B","volume":"14","author":"DA Bennett","year":"1993","unstructured":"Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS. Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. Neurobiol Aging. 1993;14:589\u201396.","journal-title":"Neurobiol Aging"},{"key":"384_CR51","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572\u201380.","journal-title":"Ann Neurol"},{"key":"384_CR52","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.tibs.2015.10.002","volume":"40","author":"KW Tipping","year":"2015","unstructured":"Tipping KW, van Oosten-Hawle P, Hewitt EW, Radford SE. Amyloid fibres: inert end-stage aggregates or key players in disease? Trends Biochem Sci. 2015;40:719\u201327.","journal-title":"Trends Biochem Sci"},{"key":"384_CR53","doi-asserted-by":"publisher","first-page":"12052","DOI":"10.1074\/jbc.M113.525212","volume":"289","author":"J Mayes","year":"2014","unstructured":"Mayes J, Tinker-Mill C, Kolosov O, Zhang H, Tabner BJ, Allsop D. beta-amyloid fibrils in Alzheimer disease are not inert when bound to copper ions but can degrade hydrogen peroxide and generate reactive oxygen species. J Biol Chem. 2014;289:12052\u201362.","journal-title":"J Biol Chem"},{"key":"384_CR54","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fnagi.2017.00083","volume":"9","author":"SS Shafiei","year":"2017","unstructured":"Shafiei SS, Guerrero-Munoz MJ, Castillo-Carranza DL. Tau oligomers: cytotoxicity, propagation, and mitochondrial damage. Front Aging Neurosci. 2017;9:83.","journal-title":"Front Aging Neurosci"},{"key":"384_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.410410106","volume":"41","author":"T G\u00f3mez-Isla","year":"1997","unstructured":"G\u00f3mez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17\u201324.","journal-title":"Ann Neurol"},{"key":"384_CR56","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/2051-5960-2-63","volume":"2","author":"N Rudinskiy","year":"2014","unstructured":"Rudinskiy N, Hawkes JM, Wegmann S, Kuchibhotla KV, Muzikansky A, Betensky RA, Spires-Jones TL, Hyman BT. Tau pathology does not affect experience-driven single-neuron and network-wide Arc\/Arg3.1 responses. Acta Neuropathol Commun. 2014;2:63.","journal-title":"Acta Neuropathol Commun"},{"key":"384_CR57","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.nlm.2011.08.003","volume":"96","author":"ST Ferreira","year":"2011","unstructured":"Ferreira ST, Klein WL. The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem. 2011;96:529\u201343.","journal-title":"Neurobiol Learn Mem"},{"key":"384_CR58","doi-asserted-by":"crossref","unstructured":"Kayed R, Lasagna-Reeves C. Molecular mechanisms of amyloid oligomers toxicity. J Alzheimers. Dis. 2013;(33 Suppl 1):S67-78.","DOI":"10.3233\/JAD-2012-129001"},{"key":"384_CR59","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000237","volume":"3","author":"EM Knight","year":"2016","unstructured":"Knight EM, Kim SH, Kottwitz JC, Hatami A, Albay R, Suzuki A, Lublin A, Alberini CM, Klein WL, Szabo P, Relkin NR, Ehrlich M, Glabe CG, Gandy S, Steele JW. Effective anti-Alzheimer Abeta therapy involves depletion of specific Abeta oligomer subtypes. Neurol Neuroimmunol Neuroinflamm. 2016;3:e237.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"384_CR60","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.neurobiolaging.2010.01.001","volume":"32","author":"DB Freir","year":"2011","unstructured":"Freir DB, Fedriani R, Scully D, Smith IM, Selkoe DJ, Walsh DM, Regan CM. Abeta oligomers inhibit synapse remodelling necessary for memory consolidation. Neurobiol Aging. 2011;32:2211\u20138.","journal-title":"Neurobiol Aging"},{"key":"384_CR61","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.bbrc.2016.09.062","volume":"483","author":"SV Salazar","year":"2017","unstructured":"Salazar SV, Strittmatter SM. Cellular prion protein as a receptor for amyloid-beta oligomers in Alzheimer's disease. Biochem Biophys Res Commun. 2017;483:1143\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"384_CR62","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/jnr.22640","volume":"89","author":"T Umeda","year":"2011","unstructured":"Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, Mori H. Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal\/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res. 2011;89:1031\u201342.","journal-title":"J Neurosci Res"},{"key":"384_CR63","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1523\/JNEUROSCI.4970-06.2007","volume":"27","author":"GM Shankar","year":"2007","unstructured":"Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866\u201375.","journal-title":"J Neurosci"},{"key":"384_CR64","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe D. Naturally secreted oligomers of amyloid b protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535\u20139.","journal-title":"Nature"},{"key":"384_CR65","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nn.3028","volume":"15","author":"I Benilova","year":"2012","unstructured":"Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349\u201357.","journal-title":"Nat Neurosci"},{"key":"384_CR66","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457\u201364.","journal-title":"Ann Neurol"},{"key":"384_CR67","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1523\/JNEUROSCI.3501-06.2007","volume":"27","author":"PN Lacor","year":"2007","unstructured":"Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci. 2007;27:796\u2013807.","journal-title":"J Neurosci"},{"key":"384_CR68","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","volume":"283","author":"J Naslund","year":"2000","unstructured":"Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571\u20137.","journal-title":"JAMA"},{"key":"384_CR69","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2174\/1567205014666170116152622","volume":"14","author":"R Krishnan","year":"2017","unstructured":"Krishnan R, Hefti F, Tsubery H, Lulu M, Proschitsky M, Fisher R. Conformation as the therapeutic target for neurodegenerative diseases. Curr Alzheimer Res. 2017;14:393\u2013402.","journal-title":"Curr Alzheimer Res"},{"key":"384_CR70","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"JC Dodart","year":"2002","unstructured":"Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452\u20137.","journal-title":"Nat Neurosci"},{"key":"384_CR71","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1074\/jbc.M511018200","volume":"281","author":"EB Lee","year":"2006","unstructured":"Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem. 2006;281:4292\u20139.","journal-title":"J Biol Chem"},{"key":"384_CR72","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1471-2202-11-130","volume":"11","author":"E Chung","year":"2010","unstructured":"Chung E, Ji Y, Sun Y, Kascsak RJ, Kascsak RB, Mehta PD, Strittmatter SM, Wisniewski T. Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci. 2010;11:130.","journal-title":"BMC Neurosci"},{"key":"384_CR73","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00401-016-1662-x","volume":"133","author":"E Drummond","year":"2017","unstructured":"Drummond E, Wisniewski T. Alzheimer's disease: experimental models and reality. Acta Neuropathol. 2017;133:155\u201375.","journal-title":"Acta Neuropathol"},{"key":"384_CR74","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.15252\/embj.201797397","volume":"36","author":"H Sasaguri","year":"2017","unstructured":"Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B, Saido TC. APP mouse models for Alzheimer's disease preclinical studies. EMBO J. 2017;36:2473\u201387.","journal-title":"EMBO J"},{"key":"384_CR75","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/17460441.2017.1271320","volume":"12","author":"D Van Dam","year":"2017","unstructured":"Van Dam D, De Deyn PP. Non human primate models for Alzheimer's disease-related research and drug discovery. Expert Opin Drug Discov. 2017;12:187\u2013200.","journal-title":"Expert Opin Drug Discov"},{"key":"384_CR76","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, and Bapineuzumab 301 and 302 clinical trial investigators (including Wisniewski, T. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322\u201333.","journal-title":"N Engl J Med"},{"key":"384_CR77","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D, McRae T, Lucas P, Evans I, Booth K, Luscan G, Wyman BT, Hua L, Yang L, Brashear HR, Black RS. Bapineuzumab and clinical study, I. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzheimers Res Ther. 2016;8:18.","journal-title":"Alzheimers Res Ther"},{"key":"384_CR78","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E. Trial of solanezumab for mild dementia due to Alzheimer's disease. N Engl J Med. 2018;378:321\u201330.","journal-title":"N Engl J Med"},{"key":"384_CR79","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"384_CR80","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","volume":"80","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer's disease. Neuron. 2013;80:1347\u201358.","journal-title":"Neuron"},{"key":"384_CR81","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/joim.12168","volume":"275","author":"L Lannfelt","year":"2014","unstructured":"Lannfelt L, Relkin NR, Siemers ER. Amyloid-ss-directed immunotherapy for Alzheimer's disease. J Intern Med. 2014;275:284\u201395.","journal-title":"J Intern Med"},{"key":"384_CR82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/alzrt233","volume":"6","author":"TE Golde","year":"2014","unstructured":"Golde TE. Open questions for Alzheimer's disease immunotherapy. Alzheimers Res Ther. 2014;6:3.","journal-title":"Alzheimers Res Ther"},{"key":"384_CR83","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/ana.410230206","volume":"23","author":"R Katzman","year":"1988","unstructured":"Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol. 1988;23:138\u201344.","journal-title":"Ann Neurol"},{"issue":"11","key":"384_CR84","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1093\/brain\/aww224","volume":"139","author":"BD James","year":"2016","unstructured":"James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain. 2016;139(11):2983\u201393.","journal-title":"Brain"},{"key":"384_CR85","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s00401-015-1406-3","volume":"129","author":"L Walker","year":"2015","unstructured":"Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, Colloby SJ, Jellinger K, Attems J. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Acta Neuropathol. 2015;129:729\u201348.","journal-title":"Acta Neuropathol"},{"key":"384_CR86","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1093\/jnen\/nlw033","volume":"75","author":"PT Nelson","year":"2016","unstructured":"Nelson PT, Trojanowski JQ, Abner EL, Al-Janabi OM, Jicha GA, Schmitt FA, Smith CD, Fardo DW, Wang WX, Kryscio RJ, Neltner JH, Kukull WA, Cykowski MD, Van Eldik LJ, Ighodaro ET. \u201cNew old pathologies\u201d: AD, PART, and cerebral age-related TDP-43 with sclerosis (CARTS). J Neuropathol Exp Neurol. 2016;75:482\u201398.","journal-title":"J Neuropathol Exp Neurol"},{"key":"384_CR87","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.neures.2017.11.012","volume":"126","author":"H Chun","year":"2018","unstructured":"Chun H, Lee CJ. Reactive astrocytes in Alzheimer's disease: a double-edged sword. Neurosci Res. 2018;126:44\u201352.","journal-title":"Neurosci Res"},{"key":"384_CR88","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0306-4522(94)90547-9","volume":"63","author":"CJ Pike","year":"1994","unstructured":"Pike CJ, Cummings BJ, Monzavi R, Cotman CW. Beta-amyloid induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease. Neurosci. 1994;63:517\u201331.","journal-title":"Neurosci"},{"key":"384_CR89","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.neurobiolaging.2008.05.015","volume":"31","author":"JE Simpson","year":"2010","unstructured":"Simpson JE, Ince PG, Lace G, Forster G, Shaw PJ, Matthews F, Savva G, Brayne C, Wharton SB, Function MRCC, and Ageing Neuropathology Study, G. Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging. 2010;31:578\u201390.","journal-title":"Neurobiol Aging"},{"key":"384_CR90","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13041-016-0191-9","volume":"9","author":"H Shoji","year":"2016","unstructured":"Shoji H, Takao K, Hattori S, Miyakawa T. Age-related changes in behavior in C57BL\/6J mice from young adulthood to middle age. Mol Brain. 2016;9:11.","journal-title":"Mol Brain"},{"key":"384_CR91","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fnmol.2016.00062","volume":"9","author":"M Huttenrauch","year":"2016","unstructured":"Huttenrauch M, Salinas G, Wirths O. Effects of long-term environmental enrichment on anxiety, memory, hippocampal plasticity and overall brain gene expression in C57BL6 mice. Front Mol Neurosci. 2016;9:62.","journal-title":"Front Mol Neurosci"},{"key":"384_CR92","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2202-8-43","volume":"8","author":"KR Magnusson","year":"2007","unstructured":"Magnusson KR, Scruggs B, Zhao X, Hammersmark R. Age-related declines in a two-day reference memory task are associated with changes in NMDA receptor subunits in mice. BMC Neurosci. 2007;8:43.","journal-title":"BMC Neurosci"},{"key":"384_CR93","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/jnen\/nlx027","volume":"76","author":"J Wegiel","year":"2017","unstructured":"Wegiel J, Flory M, Kuchna I, Nowicki K, Yong Ma S, Wegiel J, Badmaev E, Silverman WP, de Leon M, Reisberg B, Wisniewski T. Multiregional age-associated reduction of brain neuronal reserve without association with neurofibrillary degeneration or beta-amyloidosis. J Neuropathol Exp Neurol. 2017;76:439\u201357.","journal-title":"J Neuropathol Exp Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-018-0384-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-018-0384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T11:30:00Z","timestamp":1589542200000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-018-0384-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,18]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["384"],"URL":"https:\/\/doi.org\/10.1186\/s13195-018-0384-9","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,18]]},"assertion":[{"value":"21 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For human samples used during the course of this study, all procedures were performed under protocols approved by the Institutional Review Board at New York University Alzheimer\u2019s Disease Center, New York. In all cases, written informed consent for research was obtained from the patient or legal guardian, and the material used had appropriate ethical approval for use in this project. All patient data and samples were coded and handled according to NIH guidelines to protect patient identities. Animal studies performed during the course of this project were approved by the New York University School of Medicine Institutional Animal Care and Use Committee and were consistent with the recommendations of the American Veterinary Association. Mice facilities were under a strict 12-h light\/dark cycle. A general examination of the mice was conducted daily during the course of the experiment. Overall observations and any gross abnormalities in overall health, home cage nesting, behavior, grooming, and condition of the fur of the animals was noted. Body weight was measured twice during the study period.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"54"}}